Therapeutic Advances in Musculoskeletal Disease

Papers
(The TQCC of Therapeutic Advances in Musculoskeletal Disease is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge91
Pathophysiology of musculoskeletal pain: a narrative review62
Osteoporosis in 10 years time: a glimpse into the future of osteoporosis51
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of43
Promising targets for therapy of osteoarthritis: a review on the Wnt and TGF-β signalling pathways42
Psoriatic arthritis and the association with cardiometabolic disease: a narrative review42
Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders34
Opportunistic diagnosis of osteoporosis, fragile bone strength and vertebral fractures from routine CT scans; a review of approved technology systems and pathways to implementation31
Comparative effectiveness of treatment options for subacromial shoulder conditions: a systematic review and network meta-analysis29
A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening29
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)27
Moving toward targeting the right phenotype with the right platelet-rich plasma (PRP) formulation for knee osteoarthritis27
Body composition in patients with rheumatoid arthritis: a narrative literature review26
Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review26
Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders26
Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies26
Large-vessel involvement is predictive of multiple relapses in giant cell arteritis25
Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?23
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus22
A broad look into the future of rheumatoid arthritis21
Ultrasound for diagnosis and follow-up of chronic axillary vasculitis in patients with long-standing giant cell arteritis20
Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica – a prospective cohort study20
The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients19
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents19
Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe?19
Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibito19
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis18
Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study18
Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?17
Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis17
Cell-based therapies for rheumatoid arthritis: opportunities and challenges17
Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis17
Prognostic factors for 1-year functional outcome, quality of life, care demands, and mortality after surgery in Taiwanese geriatric patients with a hip fracture: a prospective cohort study16
Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review16
Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis16
Circulating microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis Initiative cohort16
Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review16
A glimpse into the future of systemic lupus erythematosus15
A glance into the future of gout15
Back pain treatment: a new perspective15
Ten-year survival analysis of patients with primary Sjögren’s syndrome in China: a national prospective cohort study14
Real-world evidence to assess the effectiveness of platelet-rich plasma in the treatment of knee degenerative pathology: a prospective observational study14
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study14
Health disparities in rheumatoid arthritis14
Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review14
Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis14
Associations between glucocorticoids, antiphospholipid antibodies and femur head necrosis in patients with SLE: a directed acyclic graph-based multicentre study13
Association between bone trace elements and osteoporosis in older adults: a cross-sectional study13
Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group12
Looking ahead: giant-cell arteritis in 10 years time12
Latest insights in disease-modifying osteoarthritis drugs development12
Efficacy and safety of biologic agents for the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials12
Sjögren syndrome: looking forward to the future12
Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs12
Inequities in people with gout: a focus on Māori (Indigenous People) of Aotearoa New Zealand12
The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities12
Soluble biological markers in osteoarthritis12
Intra-articular placebo effect in the treatment of knee osteoarthritis: a survey of the current clinical evidence12
Digital health interventions for osteoporosis and post-fragility fracture care11
Osteopathic medicine for fibromyalgia: a sham-controlled randomized clinical trial11
Interactions of the microbiome with pharmacological and non-pharmacological approaches for the management of ageing-related musculoskeletal diseases11
Interstitial lung disease pathology in systemic sclerosis11
Future challenges in rheumatology – is telemedicine the solution?11
Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis11
New insights on multigenic autoinflammatory diseases11
Increased risk of valvular heart disease in patients with ankylosing spondylitis: a nationwide population-based longitudinal cohort study11
Mesenchymal stromal cell products for intra-articular knee injections for conservative management of osteoarthritis11
Stromal vascular fraction therapy for knee osteoarthritis: a systematic review11
Gastrointestinal involvement and its association with the risk for nephritis in IgA vasculitis11
Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all11
Autologous hematopoietic stem cell transplantation modifies specific aspects of systemic sclerosis-related microvasculopathy10
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes10
Epidemiology and risk of invasive fungal infections in systemic lupus erythematosus: a nationwide population-based cohort study10
The role of adipose-derived mesenchymal stem cells in knee osteoarthritis: a meta-analysis of randomized controlled trials10
Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence10
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids10
Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case–control study10
Bone fragility during the COVID-19 pandemic: the role of macro- and micronutrients10
A glance into the future of diagnosis and treatment of spondyloarthritis10
Osteosarcopenia and Long-COVID: a dangerous combination10
0.034036874771118